

Hibernation Therapeutics USA, LLC

Innovations from Nature to Medicine

Information contained herein is intended
for education and informational purposes of the recipient ONLY

IMPORTANT INFORMATION

The formulation and use of the patented **Adenocaine® Cardioplegia** is exclusively licensed to **Central Admixture Pharmacy Services, Inc. (CAPS)** in the U.S. The patented formulation can be purchased directly from a local CAPS facility. For more information, please call (800) 853-6498 or visit www.capspharmacy.com/Adenocaine

GUIDELINES FOR THE SYRINGE PUMP DELIVERY OF ADENOCAINE® HEMODILUTED BLOOD CARDIOPLEGIA USING THE MASTER-FOLLOWER DELIVERY SYSTEM FOR ARREST, MAINTENANCE, AND REANIMATION

"Despite continuous improvements in surgical technique and cardioplegic formulations, the inadequacies of current intraoperative protection protocols and formulations, most of which contain as their basis high potassium depolarizing arrest, remain a concern."

James D. McCully JTCVS (2002)¹ p. 219-20.

The information contained in this document on hemodiluted blood cardioplegia is intended for use with a Master-Follow cardioplegia delivery system. The terminology used is consistent with standard pump system components and consumables. A separate Hibernation Therapeutics Global, Ltd. Educational Guidelines document is available for all-blood cardioplegia (microplegia) formulations using the Adenocaine® technology. See page 3 for Hibernation Therapeutics Global, Ltd. Disclaimer of Liability.

About Central Admixture Pharmacy Services (CAPS®)

State-licensed and an FDA-registered manufacturer, CAPS makes daily deliveries from an unrivaled 22 locations nationwide. Pioneered in 1991, and making more than 200,000 local deliveries annually, CAPS pharmacies reliably operate 365-days a year to dispense labeled, patient-specific and anticipatory IV prescriptions. CAPS is a B. Braun company.

Hibernation Therapeutics USA, LLC

Innovations from Nature to Medicine

Information contained herein is intended
for education and informational purposes of the recipient ONLY

TABLE OF CONTENTS

Disclaimer of Liability	3
Adenocaine® Arrest Induction, Maintenance and Reanimation	4
• Chemicals	
• Supplies	
ADENOCAINE® QUICK START GUIDE	5
• Flow Conversion Tables.....	6
• Pump / Patient Schematic Diagram.....	9
• Adenocaine® Cardioplegia Arrest, Maintenance and Reanimation	10
• Frequently Asked Questions and troubleshooting	
• Arrest Induction	10
• Maintenance	11
• Reanimation	12
• General Questions	16
DETAILED INSTRUCTIONS for Delivery of Adenocaine® Cardioplegia	20
<u>Phases of Cardioplegia</u>	
• ARREST “INDUCTION” assisted with Adenocaine®	20
• MAINTENANCE Adenocaine® with ~0-6 mEq/L K ⁺	21
• REANIMATION Adenocaine® with ~0 (Zero) mEq K ⁺ (rely on blood K ⁺)	22
BACKGROUND: Adenocaine® Arrest Induction, Maintenance and Reanimation ...	24
• Addressing an Unmet Medical Need.....	24
• Scientific Background	24
• Lessons from Natural Hibernators in Service to Cardiac Surgery	26
DEFINITIONS, DRUG PROPERTIES AND USE IN CARDIAC SURGERY	27
• Miniplegia (or Microplegia)	27
• Depolarized and Polarized Cardioplegic Arrest and Maintenance	27
• Adenosine	28
• Lidocaine-HCl	30
• MgSO ₄ 7H ₂ O.....	31
• Adenocaine®	32
APPENDIX 1. Key background Pre-clinical and Clinical Scientific Abstracts	33
• Adenosine	33
• Lidocaine	38
• Adenosine and Lidocaine	45
APPENDIX 2. About Hibernation Therapeutics and its Patent Portfolio	51
APPENDIX 3. Research Publications relevant to Hibernation Therapeutics	52
APPENDIX 4. FDA Approved Indications of Adenosine and Lidocaine	54
REFERENCES	55

Hibernation Therapeutics USA, LLC

Innovations from Nature to Medicine

Information contained herein is intended
for education and informational purposes of the recipient ONLY

Disclaimer of Liability: The document is intended for use by medically trained healthcare professionals only as a guideline for the administration of the Adenocaine® technology obtained from published and unpublished pre-clinical sources and clinical cases, and from practices currently using the technology in cardiac surgery. In preparing of these guidelines, every effort has been made to offer the most current, correct, and clearly expressed information possible. The guidelines have undergone a thorough review; nevertheless, inadvertent errors in information may occur. In particular, and not limited to, Hibernation Therapeutics Global, Ltd. (“HTG” or “Company”) parent company or any of its subsidiaries disclaims any responsibility for typographical errors affecting the accuracy of the information that may be contained in the document, or any adverse events that may arise or occur from using the information contained in this document. The Company suggests that any use made of the technology based on information included in these guidelines be subject to scientific and educational consult with the Company. The Company makes no representations or warranties regarding the functionality of this information or its suitability for use including any direct, indirect, punitive, special, incidental, or consequential damages.

HIBERNATION THERAPEUTICS GLOBAL, LTD MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND IN THE DOCUMENT AND ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, IMPLIED WARRANTIES OF SAFETY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, US FDA REGULATORY APPROVAL AND NON-INFRINGEMENT, ARE EXPRESSLY EXCLUDED FROM THIS AGREEMENT.

Hibernation Therapeutics Global, Limited or any of its subsidiaries further acknowledges and hereby gives notice that certain suggestions in the guidelines may be subject to change based on individual patient needs and surgeon preference.

To request a copy of this entire document please contact:



Hibernation Therapeutics USA, LLC
487 Cherry Street
Third Street Tower
Macon, GA 31201
www.Adenocaine.com
(o): 478-744-9994
(f): 478-744-9996